プロテインキナーゼ阻害剤、プロテインキナーゼ阻害薬

WordNet

limit, block, or decrease the action or function of; "inhibit the action of the enzyme"; "inhibit the rate of a chemical reaction"
control and refrain from showing; of emotions, desires, impulses, or behavior (同)bottle up, suppress
limit the range or extent of; "Contact between the young was inhibited by strict social customs"
any of a large group of nitrogenous organic compounds that are essential constituents of living cells; consist of polymers of amino acids; essential in the diet of animals for growth and for repair of tissues; can be obtained from meat and eggs and milk and legumes; "a diet high in protein"
a substance that retards or stops an activity
an enzyme that catalyzes the conversion of a proenzyme to an active enzyme
the basic unit of money in Papua New Guinea

PrepTutorEJDIC

〈感情・欲望・行動・作用など〉‘を'抑制する / (…しないように)〈人〉‘を'抑制する,妨げる《+『名』+『from』+『名』(do『ing』)》
蛋白(たんばく)質
抑制する人(物) / 化学反応抑制剤

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/09/07 05:20:19」(JST)

wiki en

A protein kinase inhibitor is a type of enzyme inhibitor that blocks the action of one or more protein kinases. Protein kinases are enzymes that add a phosphate (PO₄) group to a protein or other organic molecule. Phosphate groups can turn a protein off.

The phosphate groups are usually added to the serine, threonine, or tyrosine amino acid on the protein. Hence, protein kinase inhibitors can be subdivided or characterised by the amino acids whose phosphorylation is inhibited: most kinases act on both serine and threonine, the tyrosine kinases act on tyrosine, and a number (dual-specificity kinases) act on all three. There are also protein kinases that phosphorylate other amino acids, including histidine kinases that phosphorylate histidine residues.^{[citation needed]}

Phosphorylation is a necessary step in some cancers and inflammatory diseases. Inhibiting the protein kinases, and therefore the phosphorylation, can treat these diseases. Therefore, protein kinase inhibitors are used as drugs.

Clinical use

Kinase inhibitors such as dasatinib are often used in the treatment of cancer and inflammation.^{[citation needed]} The novel kinase inhibitor PLX5568 is currently in clinical trials for treatment of polycystic kidney disease as well as pain.^[1]

Some of the kinase inhibitors used in treating cancer are inhibitors of tyrosine kinases.^[2] The effectiveness of kinase inhibitors on various cancers can vary from patient to patient.^[3]

Examples

Currently there are several drugs launched or in development that target protein kinases and the receptors that activate them:

Name	Target	Company	Class	FDA approval
Afatinib	EGFR/ErbB2	Boehringer Ingelheim	Small molecule	2013 Non-small cell lung cancer
Axitinib	VEGFR1/VEGFR2/VEGFR3/PDGFRB/c-KIT	Pfizer	Small molecule	2012 Renal cell carcinoma
Bosutinib	BcrAbl /SRC	Pfizer	Small molecule	2012 Chronic myelogenous leukemia
Cetuximab	ErbB1	Imclone/BMS	Monoclonal antibody	2006 Mar (SCCHN)
Crizotinib	ALK/Met	Pfizer	Small molecule	2011 Aug (NSCLC with Alk mutation)
Dasatinib	multiple targets	BMS	Small molecule	2006
Erlotinib	ErbB1	Genentech	Small molecule	2005 Nov ?
Fostamatinib	Syk	Rigel Pharmaceuticals/AstraZeneca	Small molecule	Not yet^[4]
Gefitinib	EGFR	AstraZeneca	Small molecule	2003
Ibrutinib	BTK	Pharmacyclics	Small molecule	2013
Imatinib	Bcr-Abl	Novartis	Small molecule	2001 (CML), 2002 (GIST) ^[5]
Lapatinib	ErbB1/ErbB2	GSK	Small molecule	2007 (HER2+ Breast)
Lenvatinib	VEGFR2/VEGFR2	Eisai Co.	Small molecule	Not yet
Mubritinib	?	Takeda	Small molecule	Not yet, possibly abandoned
Nilotinib	Bcr-Abl	Novartis	Small molecule	2007
Pazopanib	VEGFR2/PDGFR/c-kit	GlaxoSmithKline	Small molecule	2009 (RCC)
Pegaptanib	VEGF	OSI/Pfizer	RNA Aptamer	2004 (AMD)
Ruxolitinib	JAK	Incyte	Small molecule	2011 (Myelofibrosis)
Sorafenib	multiple targets	Onyx/Bayer	Small molecule	2005 Dec (kidney)
Sunitinib	multiple targets	SUGEN/Pfizer	Small molecule	2006 Jan (RCC & GIST)
SU6656	multiple targets	SUGEN	Small molecule	2000 Jan (RCC & GIST)
Vandetanib	RET/VEGFR/EGFR	AstraZeneca	Small molecule	No, submission withdrawn Oct09 [1]
Vemurafenib	BRAF	Roche	Small molecule	2011 Aug Melanoma

Comparison of available agents

**Comparison of available agents used as Human Medicines**
Drug	Sponsor	Target	Indications	Major toxicities	Black box warning(s)	MS ^{[Note 1]}^[6]	D	FR	PC (AU) ^{[Note 2]}	PC (US) ^{[Note 3]}	FDA AD^[7]	EMA AD^[8]	TGA AD^[9]
Afatinib	Boehringer Ingelheim	ErbB family (irreversible)	Advanced non-small cell lung cancer	Hepatotoxicity, kidney failure, electrolyte anomalies (mostly hypokalaemia) and interstitial lung disease (uncommon).	None	-	+++	-	C	D	12 July 2013	25 September 2013	7 November 2013
Aflibercept	Bayer, Regeneron	VEGF	Advanced colorectal cancer and wet macular degeneration.	GI perforation, haemorrhage and hepatotoxicity	None	+++/++	+++/++	-	D	C	21 November 2011	22 November 2012	2 April 2013
Axitinib	Pfizer	VEGFR, PDGFR, c-KIT	Renal cell carcinoma	Thyroid dysfunction, blood clots, haemorrhages, reversible posterior leucoencephalopathy syndrome (uncommon), GI perforation/fistula (uncommon) and electrolyte disturbances	None	++	++	-	D	D	27 January 2012	3 September 2012	26 July 2012
Bevacizumab	Genentech	VEGF	Colorectal cancer, breast cancer, non-small cell lung cancer, renal cell carcinoma, macular degeneration and glioblastoma	Hypertension, GI perforation, ovarian failure, GI haemorrhage, blood clots, electrolyte anomalies, ileus, congestive heart failure, osteonecrosis of the jaw (rare), necrotising fasciitis (rare), gallbladder perforation (rare)	GI perforation, haemorrhage and wound healing complications	++	++/+	-	D	C	26 February 2004	12 January 2005	24 February 2005
Bosutinib	Pfizer	Bcr-Abl	Second-line Chronic myelogenous leukaemia treatment	Lower respiratory tract infection, anaphylaxis (uncommon), electrolyte anomalies, cardiovascular effects (especially QT interval prolongation), GI haemorrhage (uncommon), hepatotoxicity and kidney failure.	None	++/+	+++	+	N/A	D	4 September 2012	27 March 2013	N/A
Cabozantinib	Exelixis	c-Met, VEGFR2	Metastatic thyroid cancer	Electrolyte anomalies, hypotension, peripheral sensory neuropathy, GI perforation/fistula, reversible posterior leucoencephalopathy syndrome (rare), blood clots and osteonecrosis.	GI haemorrhage, perforation and fistula	++	+++/++	-	N/A	D	29 November 2012	N/A	N/A
Crizotinib	Pfizer	ALK, HGFR, c-MET	Anaplastic lymphoma kinase-positive non-small cell lung cancer	Peripheral neuropathy, electrolyte anomalies, blood clots, kidney cyst, liver failure, interstitial lung disease and cardiotoxicity (probably QT interval prolongation).	None	++	++	++/+	D	D	26 August 2011	23 October 2012	27 September 2013
Dasatinib	Bristol-Myers Squibb	Bcr-Abl, Src, c-KIT	Second-line Chronic myelogenous leukaemia treatment	Electrolyte disturbances, haemorrhages, fluid retention, heart failure (uncommon), myocardial infarction (uncommon) and pulmonary hypertension	None	+/-	++	++	D	D	28 June 2006	20 November 2006	15 January 2007
Erlotinib	Roche	EGFR	Advanced non-small cell lung cancer and pancreatic cancer	GI bleeds (rare), liver failure (rare), hepatorenal syndrome (rare), EGFR skin reactions and interstitial lung disease(uncommon).	None	-	+++/++	-	C	D	18 November 2004	19 September 2005	30 January 2006
Gefitinib	AstraZeneca, Teva	EGFR	Advanced non-small cell lung cancer with EGFR mutation	Haemorrhage, EGFR skin reactions (including Stevens-Johnson syndrome [SJS; rare] and toxic epidermal necrolysis[TEN; rare]), liver failure (rare), hepatitis (uncommon), pancreatitis (uncommon) and interstitial lung disease (uncommon).	N/A	-	+++/++	-	C	D	5 May 2003 (discontinued)	24 June 2009	7 September 2011
Imatinib	Novartis	Bcr-Abl	First-line chronic myelogenous leukaemia treatment	Haemorrhage, electrolyte disturbances, cardiotoxicity (uncommon), kidney failure (uncommon), GI perforation, hepatotoxicity (rare) and rhabdomyolysis (rare)	N/A	+++/++	+	++	D	D	10 May 2001	7 November 2001	13 August 2001
Lapatinib	GlaxoSmithKline	HER2	HER2-positive advanced breast cancer	Hypersensitivity (rare), hepatotoxicity (uncommon), interstitial lung disease (uncommon) and cardiovascular problems.	Hepatotoxicity	-	++	-	C	D	13 March 2007	10 June 2008	28 June 2007
Nilotinib	Novartis	Bcr-Abl	Second-line chronic myelogenous leukaemia treatment	Hyperglycaemia, electrolyte disturbances, fluid retention, pancreatitis and cardiotoxicity (mostly QT interval prolongation).	QT interval prolongation and electrolyte anomalies	++	+	+	D	D	29 October 2007	2 June 2009	17 January 2008
Panitumumab	Amgen	EGFR	Colorectal cancer	Electrolyte anomalies, anaphylaxis, blood clots, sepsis and pulmonary fibrosis.	Dermatologic reactions and infusion reactions	-	+	+	C	C	10 October 2006	3 December 2007	20 March 2012
Pazopanib	GlaxoSmithKline	VEGFR, PDGFR, c-KIT	Renal cell carcinoma and soft tissue sarcoma	Cardiotoxicity (mostly QT interval prolongation but also heart failure [uncommon]), blood clots, haemorrhage, thyroid anomalies (mostly hypothyroidism), blood glucose anomalies (hypoglycaemia and hyperglycaemia), torsades de pointes (uncommon), hepatotoxicity (uncommon), GI perforation/fistula (uncommon) and reversible posterior leucoencephalopathy syndrome (rare).	Hepatotoxicity	-	++	-	D	D	19 October 2009	14 June 2010	30 June 2010
Pegaptanib	OSI, Pfizer	VEGF	Wet macular degeneration	Hypertension, cataracts, haemorrhage, vitreous floater, transient ischaemic attack, retinal detachment, diabetes mellitus and urinary tract infection	None	-	+/-	++	N/A	B	17 December 2004	31 January 2006	N/A
Ponatinib	ARIAD Pharmaceuticals	Bcr-Abl, BEGFR, PDGFR, FGFR, EPH, SRC, c-KIT, RET, TIE2, FLT3	T315I-positive Chronic myelogenous leukaemia and T315I-positive-Acute lymphoblastic leukaemia	Hypertension, pneumonia, urinary tract infection, sepsis, GI haemorrhage, liver failure, cardiovascular problems and blood clots.	Liver failure, blood clots and hepatotoxicity	++	+	+	N/A	D	14 December 2012	1 July 2013	N/A
Ranibizumab	Novartis	VEGF-A	Wet macular degeneration and macular oedema (including diabetic macular oedema)	Haemorrhage (conjunctival, vitreous and injection site), increased intraocular pressure, vitreous detachment and retinal degeneration.	None	-	-	-	D	C	10 August 2012	22 January 2007	27 February 2007
Regorafenib	Bayer	RET, VEGFR, PDGFR	Advanced colorectal cancer, gastrointestinal stromal tumours	Electrolyte anomalies, hepatotoxicity, hypotension, haemorrhage, GI fistula, thyroid problems and blood clots.	Hepatotoxicity	+++/++	++	-	D	D	27 September 2012	26 August 2013	29 November 2013
Ruxolitinib	Novartis	JAK	Myelofibrosis	Hypercholesterolaemia, urinary tract infection, herpes zoster, tuberculosis and hepatotoxicity	None	+++	-	-	C	C	16 November 2011	23 August 2012	3 July 2013
Sorafenib	Bayer	VEGFR, PDGFR, BRAF, c-KIT, etc.	Advanced Renal cell carcinoma and Hepatocellular carcinoma	Hypertension, peripheral neuropathy, thyroid dysfunction, cardiovascular problems (e.g. QT interval prolongation, heart attack or heart failure), electrolyte anomalies, GI perforation (uncommon), pancreatitis (uncommon), hepatitis (rare), nephrotic syndrome (rare) and reversible posterior leucoencephalopathy syndrome (rare)	None	++	++	-	D	D	20 December 2005	19 July 2006	27 September 2006
Sunitinib	Pfizer	VEGFR, PDGFR	Renal cell carcinoma, GI stromal tumour, pancreatic neuroendocrine tumour	Blood clots, cardiovascular problems (mostly heart failure or left ventricular dysfunction but also QT interval prolongation and torsades de pointes), thyroid dysfunction, electrolyte anomalies, skin reactions (including SJS [rare] and TEN [rare]), liver failure (uncommon) and pancreatitis (uncommon).	Hepatotoxicity	+	++	+	D	D	26 January 2006	19 July 2006	14 September 2006
Tofacitinib	Pfizer	JAK	Rheumatoid arthritis	Infections and malignancies	Serious infections and malignancies	-	-	-	N/A	C	6 November 2012	N/A; refused 26 April 2013	N/A
Trastuzumab	Genentech	HER2	Breast cancer (for either metastatic disease or adjuvant treatment), metastatic gastric cancer	Congestive heart failure, depression, pulmonary toxicity, infections and tachycardia (heart high rate)	Pulmonary toxicity, cardiomyopathy and a confusion warning	-	+	+	B2	D	25 September 1998	28 August 2000	14 September 2000
Vandetanib	AstraZeneca	VEGFR, EGFR, RET, BRK	Advanced medullary thyroid cancer	Urinary tract infection, hypertension, QT interval prolongation, electrolyte anomalies, depression, GI perforation and thyroid anomalies	QT interval prolongation	-	++	-	D	D	21 April 2011	17 February 2012	31 January 2013
Vemurafenib	Roche	BRAF	Metastatic malignant melanoma	Photosensitivity, squamous cell carcinoma and hepatotoxicity	None	-	+	+	D	D	17 August 2011	10 May 2012	17 February 2012

Note:
AD = Approval date.
MS = Myelosuppression.
D = Diarrhoea.
FR = Fluid retention.
As far as myelosuppression, diarrhoea and fluid retention goes: +++ means >70% of patients exhibit clinically significant myelosuppression. ++ means 30-70% of patients exhibit significant myelosuppression. + means 10-30% of patients exhibit significant myelosuppression. - means 0-10% of patients exhibit this side effect.
General references templates are given, which refer the reader to the respective drug database.

^ Myelosuppression.
^ PC = Pregnancy category
^ PC = Pregnancy category

References

^ "Plexxikon Initiates Phase 1 Trial for PLX5568".
^ "Definition of tyrosine kinase inhibitor - NCI Dictionary of Cancer Terms".
^ Jänne, Pasi A.; Gray, Nathanael; Settleman, Jeff (2009). "Factors underlying sensitivity of cancers to small-molecule kinase inhibitors". Nature Reviews Drug Discovery 8 (9): 709–23. doi:10.1038/nrd2871. PMID 19629074.
^ Bajpai, M (2009). "Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases". IDrugs 12 (3): 174–85. PMID 19333898.
^ "FDA Grants Imatinib (Gleevec) Full Approval for Adjuvant Treatment of GIST".
^ "Medscape Multispecialty – Home page". WebMD. Retrieved 27 November 2013. ^{[full citation needed]}
^ monograph
^ "European Public Assessment Reports". European Medicines Agency. Retrieved 27 January 2014. ^{[full citation needed]}
^ "Therapeutic Goods Administration – Home page". Department of Health (Australia). Retrieved 27 November 2013. ^{[full citation needed]}

External links

Protein kinase inhibitors at the US National Library of Medicine Medical Subject Headings (MeSH)
IC50 values for common inhibitors
"Table 1: Chemical structures and known kinase targets for clinically approved kinase inhibitors". in Jänne, Pasi A.; Gray, Nathanael; Settleman, Jeff (2009). "Factors underlying sensitivity of cancers to small-molecule kinase inhibitors". Nature Reviews Drug Discovery 8 (9): 709–23. doi:10.1038/nrd2871. PMID 19629074.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. Reperfusion injury of the heart
2. 慢性骨髄性白血病の細胞生物学および分子生物学 cellular and molecular biology of chronic myeloid leukemia
3. 未分化リンパ腫キナーゼ（ALK）融合癌遺伝子陽性非小細胞肺癌 anaplastic lymphoma kinase alk fusion oncogene positive non small cell lung cancer
4. 進行非小細胞肺癌に対する遺伝子型による個別治療 personalized genotype directed therapy for advanced non small cell lung cancer
5. アントラサイクリン系以外の癌化学療法剤の心毒性 cardiotoxicity of nonanthracycline cancer chemotherapy agents

English Journal

Activation of RAW 264.7 cells by a polysaccharide isolated from Antarctic bacterium Pseudoaltermonas sp. S-5.

Li J1, Qian W2, Xu Y2, Chen G3, Wang G2, Nie S4, Shen B4, Zhao Z2, Liu C2, Chen K5.
Carbohydrate polymers.Carbohydr Polym.2015 Oct 5;130:97-103. doi: 10.1016/j.carbpol.2015.04.070. Epub 2015 May 12.
The aim of this study was to examine the effect of extracellular polysaccharide (PEP) from Antarctic bacterium Pseudoaltermonas sp. S-5 on RAW 264.7 cells together with the underlying signaling pathways. Our results illustrated that PEP induced dendritic-like morphological change in RAW 264.7 cells,
PMID 26076605

Plasmonic ruler on field-effect devices for kinase drug discovery applications.

Bhalla N1, Formisano N2, Miodek A3, Jain A4, Di Lorenzo M5, Pula G6, Estrela P7.
Biosensors & bioelectronics.Biosens Bioelectron.2015 Sep 15;71:121-8. doi: 10.1016/j.bios.2015.04.020. Epub 2015 Apr 8.
Protein kinases are cellular switches that mediate phosphorylation of proteins. Abnormal phosphorylation of proteins is associated with lethal diseases such as cancer. In the pharmaceutical industry, protein kinases have become an important class of drug targets. This study reports a versatile appro
PMID 25897881

Diallyl trisulfide protects against high glucose-induced cardiac apoptosis by stimulating the production of cystathionine gamma-lyase-derived hydrogen sulfide.

Tsai CY1, Wen SY2, Shibu MA3, Yang YC4, Peng H5, Wang B5, Wei YM4, Chang HY6, Lee CY7, Huang CY8, Kuo WW9.
International journal of cardiology.Int J Cardiol.2015 Sep 15;195:300-10. doi: 10.1016/j.ijcard.2015.05.111. Epub 2015 May 20.
BACKGROUND: Cystathionine-γ-lyase (CSE)-derived hydrogen sulfide (H2S) is a potent cardioprotective agent. We investigated the effects of diallyl trisulfide (DATS) on CSE expression and H2S generation in myocardium and examined whether DATS-mediated H2S generation effectively protects rat heart fro
PMID 26056963

Japanese Journal

Novel Antitumor Invasive Actions of p-Cymene by Decreasing MMP-9/TIMP-1 Expression Ratio in Human Fibrosarcoma HT-1080 Cells

Biological & pharmaceutical bulletin 39(8), 1247-1253, 2016-08
NAID 40020899460

SCFFbl12 Increases p21Waf1/Cip1 Expression Level through Atypical Ubiquitin Chain Synthesis

Molecular and cellular biology 36(16), 2182-2194, 2016-08
NAID 120005851306

Kinases in lung cancer

呼吸器内科 = Respiratory medicine 30(1), 74-78, 2016-07
NAID 40020920090

Related Pictures

★リンクテーブル★

リンク元	「プロテインキナーゼ阻害剤」「プロテインキナーゼ阻害薬」
関連記事	「inhibit」「inhibitor」「kinase」「protein kinase」「kinase inhibitor」